NIOSH Current Intelligence Bulletin: Reproductive Risks Associated With Hazardous Drug Exposures in Healthcare Workers and Recommendations for Reducing Exposures, 3601-3602 [2015-01209]
Download as PDF
<![CDATA[
3601
Federal Register / Vol. 80, No. 15 / Friday, January 23, 2015 / Notices
community. The data will be translated
for practitioners and others engaged in
parent training work. Data that are
collected will be stored physically and
electronically by the contractors
collecting the respective data at their
offices. De-identified electronic
database(s) will be transferred to CDC.
Any hard copies of data will be
destroyed after the data has been
successfully entered, cleaned and
backed up into the database. We
anticipate that the surveys will take
nurturing relationships and
environments for children, then CDC
has a resource that can be easily and
freely disseminated to communities.
Ultimately, the results of the work will
be disseminated to researchers, states,
and the public.
There are no costs to the respondents
other than their time. The total
estimated annual burden hours are
1,950.
between 15 minutes to 45 minutes to
complete (depending on which survey
is being completed).
The proposed data collection fits into
the National Center for Injury
Prevention and Control Research
Agenda Priorities in Preventing Child
Maltreatment. Research is essential to
ensure effects on parenting are achieved
using the new delivery platform. If
Essentials for Parenting Toddlers and
Preschoolers is successful at increasing
positive parenting and safe, stable,
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hrs)
Total burden
(in hrs)
Type of respondent
Form name
Parents (both Natural Navigation
[NN] and Guided Navigation [GN]
groups).
Screening and Demographics Questionnaires.
200
1
15/60
50
Detailed Assessment Measures ......
Core Assessment Measures (Rotating).
Parental EFP Skills Knowledge
Scale.
Parental EFP Skills Usefulness
Scale.
Therapy Attitude Inventory and System Usability Scale.
200
200
2
16
45/60
15/60
300
800
200
10
15/60
500
200
5
15/60
250
200
1
15/60
50
........................
........................
........................
1,950
Total ...........................................
...........................................................
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2015–01093 Filed 1–22–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention (CDC)
[CDC–2015–0003, Docket Number NIOSH–
279]
NIOSH Current Intelligence Bulletin:
Reproductive Risks Associated With
Hazardous Drug Exposures in
Healthcare Workers and
Recommendations for Reducing
Exposures
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Request for information and
comment.
tkelley on DSK3SPTVN1PROD with NOTICES
AGENCY:
VerDate Sep<11>2014
18:05 Jan 22, 2015
Jkt 235001
The National Institute for
Occupational Safety and Health of the
Centers for Disease Control and
Prevention announces the availability of
a draft Current Intelligence Bulletin
entitled NIOSH Current Intelligence
Bulletin: Reproductive Risks Associated
with Hazardous Drug Exposures in
Healthcare Workers and
Recommendations for Reducing
Exposures now available for public
comment. To view the notice and
related materials, visit https://
www.regulations.gov and enter CDC–
2015–0003 in the search field and click
‘‘Search.’’
Public comment period: Electronic or
written comments must be received
March 24, 2015.
ADDRESSES: You may submit comments,
identified by CDC–2015–0003 and
Docket Number NIOSH–279, by either
of the following two methods:
• Federal eRulemaking Portal: https://
www.regulations.gov Follow the
instructions for submitting comments.
• Mail: National Institute for
Occupational Safety and Health, NIOSH
Docket Office, 1090 Tusculum Avenue,
MS C–34, Cincinnati, Ohio 45226–1998.
Instructions: All information received
in response to this notice must include
the agency name and docket number
[CDC–2015–0003; NIOSH–279]. All
SUMMARY:
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
relevant comments received will be
posted without change https://
www.regulations.gov, including any
personal information provided. All
information received in response to this
notice will also be available for public
examination and copying at the NIOSH
Docket Office, 1150 Tusculum Avenue,
Room 155, Cincinnati, OH 45226.
SUPPLEMENTARY INFORMATION:
Background: The NIOSH Current
Intelligence Bulletin: Reproductive
Risks Associated with Hazardous Drug
Exposures in Healthcare Workers and
Recommendations for Reducing
Exposures reviews and summarizes all
published studies on adverse
reproductive effects of occupational
exposures to antineoplastic drugs.
Hazardous drugs, especially
antineoplastic drugs, are some of the
most potent teratogenic chemicals
known. In addition, they can affect
germinal cells, reproduction, and
exposures can result in spontaneous
abortion. This document summarizes
results of animal studies, occupational
epidemiology studies, as well as adverse
effects that have been observed in
patients treated with these drugs. While
workplaces should be safe for all
employees, the unique sensitivity of the
developing fetus and the infant who is
E:\FR\FM\23JAN1.SGM
23JAN1
3602
Federal Register / Vol. 80, No. 15 / Friday, January 23, 2015 / Notices
breastfeeding necessitate the need for
extra precautions when these drugs are
handled by both males and females who
are trying to conceive, women who may
become or who are pregnant, and
women who are breast feeding.
Recommendations for temporary
reassignment of duties or alternative
duty are included in this guidance
document.
Information Needs: Additional data
and information are needed to assist
NIOSH to protect the reproductive
health of healthcare workers who come
in contact with antineoplastic drugs.
Information is needed for: (1)
Appropriateness of guidance, (2) Effect
on work practices, (3) Confidentiality
issues, (4) Financial impact.
NIOSH seeks to obtain materials,
including published and unpublished
reports and research findings, to
evaluate:
• Relevant publications not included
in this document
• Institutional and organizational
policies in effect
• Other relevant information related
to this topic
References
tkelley on DSK3SPTVN1PROD with NOTICES
Connor TH, DeBord G, Pretty JR, Oliver
MS, Roth TS, Lees PSJ, Krieg EF,
Rogers B, Escalante CP, Toennis CA,
Clark JC, Johnson B, McDiarmid MA
[2010]. Evaluation of antineoplastic
drug exposure of health care workers
at three university-based US cancer
centers. J Occup Environ Med
52:1019–1027.
Connor TH, Lawson CC, Polovich M,
McDiarmid MA [2014]. Reproductive
health risks associated with
occupational exposures to
antineoplastic drugs in health care
settings. JOEM 56: 901–10.
Lawson CC, Rocheleau CM, Whelan EA,
Lividoti Hibert EN, Grajewski B,
Spiegelman D, Rich-Edwards JW
[2012]. Occupational exposures
among nurses and risk of spontaneous
abortions. Am J Obstet Gynecol
206(327):e1–8.
FOR FURTHER INFORMATION CONTACT:
Thomas H. Connor, NIOSH, Division of
Applied Research and Technologies,
Robert A. Taft Laboratories, 1090
Tusculum Avenue, MS–C23, Cincinnati,
Ohio 45226, Phone: (513) 533–8399,
Email: hazardousdrugs@cdc.gov.
Dated: January 15, 2015.
John Howard,
Director, National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
[FR Doc. 2015–01209 Filed 1–22–15; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014
18:05 Jan 22, 2015
Jkt 235001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[CDC–2015–0002, Docket Number NIOSH–
244–A]
Request for Comment on the Second
Decade of National Occupational
Research Agenda (NORA)
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Request for information and
comment.
AGENCY:
The National Institute for
Occupational Safety and Health of the
Centers for Disease Control and
Prevention announces the availability of
NIOSH Docket Number 244–A entitled
Request for Comment on the Second
Decade of NORA for public comment.
To view the notice, visit https://
www.regulations.gov and enter CDC–
2015–0002 in the search field and click
‘‘Search.’’
Public comment period: Electronic or
written comments must be received by
March 24, 2015.
ADDRESSES: You may submit comments,
identified by CDC–2015–0002 and
Docket Number NIOSH–244–A, by
either of the following two methods:
• Federal eRulemaking Portal: https://
www.regulations.gov Follow the
instructions for submitting comments.
• Mail: National Institute for
Occupational Safety and Health, NIOSH
Docket Office, 1090 Tusculum Avenue,
MS C–34, Cincinnati, Ohio 45226–1998.
Instructions: All information received
in response to this notice must include
the agency name and docket number
[CDC–2015–0002; NIOSH–244–A]. All
relevant comments received will be
posted without change to https://
www.regulations.gov, including any
personal information provided. All
electronic comments should be
formatted in Microsoft Word. All
information received in response to this
notice will also be available for public
examination and copying at the NIOSH
Docket Office, 1150 Tusculum Avenue,
Room 155, Cincinnati, OH 45226.
SUPPLEMENTARY INFORMATION:
Background: The National Institute
for Occupational Safety and Health
(NIOSH) is evaluating the impact of the
National Occupational Research Agenda
(NORA, https://www.cdc.gov/niosh/
nora/). NORA is a partnership program
to stimulate innovative research and
SUMMARY:
PO 00000
Frm 00056
Fmt 4703
Sfmt 9990
improved workplace practices. Begun in
1996, NORA has become a research
framework for NIOSH and the nation.
Diverse parties collaborate to identify
the most critical issues in workplace
safety and health. Partners work
together to develop goals and objectives
for addressing these needs. Participation
in NORA is broad, including
stakeholders from universities, large and
small businesses, professional societies,
government agencies, and worker
organizations.
The program entered its second
decade in 2006 with a new sector based
structure to better move research to
practice within workplaces. The
national agenda is developed and
implemented through the NORA Sector
Councils. Each Council develops and
maintains an agenda for its sector
(https://www.cdc.gov/niosh/nora/). The
collection of national sector agendas is
the agenda for the nation for
improvements in occupational safety
and health through research and
partnerships. Representing all
stakeholders, the councils use an open
process to set goals, develop strategies,
encourage partnerships, and promote
improved workplace practices.
NIOSH is reviewing the
accomplishments of the second decade
of NORA and is preparing for the third
decade, which will start in 2016. As a
part of this review, NIOSH is seeking
comments from partners and the public
to evaluate the second decade and plan
for the third decade of NORA. NIOSH is
requesting the following feedback:
Please describe the most significant
successes and challenges of your engagement
with NIOSH during the second decade of
NORA (2006 to present).
FOR FURTHER INFORMATION CONTACT:
Sidney C. Soderholm, Ph.D., NORA
Coordinator, CDC—National Institute
for Occupational Safety and Health, 395
E St. SW., Suite 9200, Washington, DC
20201 or call (202) 245–0665. This is
not a toll free number.
Dated: January 15, 2015.
John Howard,
Director, National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
[FR Doc. 2015–01208 Filed 1–22–15; 8:45 am]
BILLING CODE 4163–19–P
E:\FR\FM\23JAN1.SGM
23JAN1
]]>Agencies
[Federal Register Volume 80, Number 15 (Friday, January 23, 2015)]
[Notices]
[Pages 3601-3602]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-01209]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention (CDC)
[CDC-2015-0003, Docket Number NIOSH-279]
NIOSH Current Intelligence Bulletin: Reproductive Risks
Associated With Hazardous Drug Exposures in Healthcare Workers and
Recommendations for Reducing Exposures
AGENCY: National Institute for Occupational Safety and Health (NIOSH)
of the Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Request for information and comment.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health of
the Centers for Disease Control and Prevention announces the
availability of a draft Current Intelligence Bulletin entitled NIOSH
Current Intelligence Bulletin: Reproductive Risks Associated with
Hazardous Drug Exposures in Healthcare Workers and Recommendations for
Reducing Exposures now available for public comment. To view the notice
and related materials, visit https://www.regulations.gov and enter CDC-
2015-0003 in the search field and click ``Search.''
Public comment period: Electronic or written comments must be
received March 24, 2015.
ADDRESSES: You may submit comments, identified by CDC-2015-0003 and
Docket Number NIOSH-279, by either of the following two methods:
Federal eRulemaking Portal: https://www.regulations.gov
Follow the instructions for submitting comments.
Mail: National Institute for Occupational Safety and
Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C-34, Cincinnati,
Ohio 45226-1998.
Instructions: All information received in response to this notice
must include the agency name and docket number [CDC-2015-0003; NIOSH-
279]. All relevant comments received will be posted without change
https://www.regulations.gov, including any personal information
provided. All information received in response to this notice will also
be available for public examination and copying at the NIOSH Docket
Office, 1150 Tusculum Avenue, Room 155, Cincinnati, OH 45226.
SUPPLEMENTARY INFORMATION:
Background: The NIOSH Current Intelligence Bulletin: Reproductive
Risks Associated with Hazardous Drug Exposures in Healthcare Workers
and Recommendations for Reducing Exposures reviews and summarizes all
published studies on adverse reproductive effects of occupational
exposures to antineoplastic drugs. Hazardous drugs, especially
antineoplastic drugs, are some of the most potent teratogenic chemicals
known. In addition, they can affect germinal cells, reproduction, and
exposures can result in spontaneous abortion. This document summarizes
results of animal studies, occupational epidemiology studies, as well
as adverse effects that have been observed in patients treated with
these drugs. While workplaces should be safe for all employees, the
unique sensitivity of the developing fetus and the infant who is
[[Page 3602]]
breastfeeding necessitate the need for extra precautions when these
drugs are handled by both males and females who are trying to conceive,
women who may become or who are pregnant, and women who are breast
feeding. Recommendations for temporary reassignment of duties or
alternative duty are included in this guidance document.
Information Needs: Additional data and information are needed to
assist NIOSH to protect the reproductive health of healthcare workers
who come in contact with antineoplastic drugs. Information is needed
for: (1) Appropriateness of guidance, (2) Effect on work practices, (3)
Confidentiality issues, (4) Financial impact.
NIOSH seeks to obtain materials, including published and
unpublished reports and research findings, to evaluate:
Relevant publications not included in this document
Institutional and organizational policies in effect
Other relevant information related to this topic
References
Connor TH, DeBord G, Pretty JR, Oliver MS, Roth TS, Lees PSJ, Krieg EF,
Rogers B, Escalante CP, Toennis CA, Clark JC, Johnson B, McDiarmid MA
[2010]. Evaluation of antineoplastic drug exposure of health care
workers at three university-based US cancer centers. J Occup Environ
Med 52:1019-1027.
Connor TH, Lawson CC, Polovich M, McDiarmid MA [2014]. Reproductive
health risks associated with occupational exposures to antineoplastic
drugs in health care settings. JOEM 56: 901-10.
Lawson CC, Rocheleau CM, Whelan EA, Lividoti Hibert EN, Grajewski B,
Spiegelman D, Rich-Edwards JW [2012]. Occupational exposures among
nurses and risk of spontaneous abortions. Am J Obstet Gynecol
206(327):e1-8.
FOR FURTHER INFORMATION CONTACT: Thomas H. Connor, NIOSH, Division of
Applied Research and Technologies, Robert A. Taft Laboratories, 1090
Tusculum Avenue, MS-C23, Cincinnati, Ohio 45226, Phone: (513) 533-8399,
Email: hazardousdrugs@cdc.gov.
Dated: January 15, 2015.
John Howard,
Director, National Institute for Occupational Safety and Health,
Centers for Disease Control and Prevention.
[FR Doc. 2015-01209 Filed 1-22-15; 8:45 am]
BILLING CODE 4163-18-P
